Related Experiment Video

Updated: Jun 20, 2026

Stimulation of Notch Signaling in Mouse Osteoclast Precursors
08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

Enhanced inhibitory effects of a novel CpG motif on osteoclast differentiation via TREM-2 down-regulation

Jae-Ho Chang1, Eun-Ju Chang, Hong-Hee Kim

  • 1Institute of Basic Medical Science, Wonju College of Medicine, Yonsei University, Wonju 220-710, South Korea.

Biochemical and Biophysical Research Communications
|August 25, 2009
PubMed

Insights

A new CpG-KSK13 oligonucleotide effectively inhibits osteoclastogenesis, blocking bone loss by down-regulating TREM-2 expression. This agent shows potential for treating bone diseases in both humans and animals.

Area of Science:

  • Immunology
  • Cell Biology
  • Bone Biology

Background:

  • Toll-like receptor 9 (TLR9) recognizes CpG motifs in oligodeoxynucleotides (CpG-ODNs).
  • CpG-ODNs can inhibit RANKL-induced osteoclastogenesis but also enhance it in primed cells, limiting clinical use.
  • Pathological bone loss is a significant clinical concern, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To develop and evaluate a novel CpG oligonucleotide (CpG-KSK13) for inhibiting osteoclastogenesis.
  • To compare the efficacy of CpG-KSK13 with existing CpG motifs (CpG-1826, CpG-2006) in preclinical models.
  • To elucidate the molecular mechanisms underlying CpG-KSK13's anti-osteoclastogenic effects.

Main Methods:

  • Development of CpG-KSK13 with an alternative CpG motif.
  • Testing CpG-ODN effects on osteoclast formation from bone marrow-derived macrophages (BMMs) and RANKL-primed pre-osteoclasts (pOCs).
  • Assessing CpG-ODN effects on human osteoclast differentiation using peripheral blood mononuclear cells (PBMCs).
  • Analyzing the impact of CpG-KSK13 on transcription factor activity (NFATc1, NF-kappaB, AP-1) and TREM-2 expression.

Main Results:

  • CpG-KSK13 potently inhibited osteoclast formation from both BMMs and primed pOCs, unlike CpG-1826.
  • CpG-KSK13 demonstrated broad efficacy in both murine and human osteoclast differentiation models.
  • CpG-KSK13 suppressed NFATc1 activity and decreased TREM-2 promoter activity and surface expression.

Conclusions:

  • CpG-KSK13 inhibits osteoclastogenesis via TLR9 by down-regulating TREM-2 expression.
  • CpG-KSK13 represents a promising therapeutic agent for preventing pathological bone loss in humans and animals.
  • The novel CpG-KSK13 offers a more effective strategy than previous CpG-ODNs for controlling osteoclast differentiation.

More Related Videos

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...